The development of GIPR–GLP-1R co-agonists have been a major advancement in the treatment of obesity and diabetes9, but the mechanisms through which GIP affects systemic energy metabolism remain largely unknown. This evidence concerns the gene GIPR and obesity due to melanocortin 4 receptor deficiency.